Q2 2026 saw improved profitability, strong cash reserves, and robust pipeline progress, with revenue rising year-over-year and operating losses narrowing sharply. Diagnostics and pharma segments both contributed to growth, while guidance for 2026 was raised.

Based on

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.